[Management of Primary Ciliary Dyskinesia]

Area of Science:

• Genetics and Rare Diseases
• Pulmonology
• Cilia Biology

Background:

• Primary Ciliary Dyskinesia (PCD) is a rare, inherited disorder impacting motile cilia function across multiple organs.
• The hallmark symptom is chronic airway infection due to impaired mucus clearance, potentially causing irreversible lung damage and respiratory failure.
• Currently, evidence-based treatments for PCD are limited, with no definitive cure available.

Purpose of the Study:

• To review and consolidate current management strategies for Primary Ciliary Dyskinesia (PCD).
• To provide a consensus overview of PCD care based on expert opinion and clinical experience.
• To highlight the need for evidence-based treatments and ongoing research initiatives in PCD.

Main Methods:

• Consensus development involving experienced clinicians and patient representatives specializing in PCD care.
• Review of existing treatment approaches, often extrapolated from other lung diseases like cystic fibrosis (CF), COPD, and bronchiectasis.
• Identification of ongoing research projects, such as the International PCD Registry, to foster evidence generation.

Main Results:

• Treatment strategies for PCD primarily rely on expert consensus, clinical experience, and data from related respiratory conditions.
• Current management focuses on routine airway clearance and addressing recurrent respiratory infections.
• Non-respiratory symptoms are managed on an organ-specific basis.
• The first placebo-controlled trial in PCD has been published, marking a significant step towards evidence-based pharmacotherapy.

Conclusions:

• There is a critical need for more evidence-based treatment guidelines for Primary Ciliary Dyskinesia (PCD).
• Patient registries and genotype-specific research are crucial for advancing knowledge and personalizing care for PCD patients.
• Collaborative efforts between clinicians, researchers, and patients are essential for improving outcomes in PCD management.